PDCD1 and lymphoma: This success extended to other cancer models like D4M.3A melanoma and A20 lymphoma, where CLF + ICB therapy not only eradicated tumors but also confirmed CLF’s role in augmenting the therapeutic reach of anti-PD-1 + CTLA-4 therapy, marking a significant stride in refining ICB therapy to increase its application and improve tolerability.